Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer

Al Murri, A.M., Bartlett, J.M.S., Canney, P.A., Doughty, J.C., Wilson, C. and McMillan, D.C. (2006) Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. British Journal of Cancer, 94(2), pp. 227-230. (doi:10.1038/sj.bjc.6602922.)

Full text not currently available from Enlighten.

Abstract

Prediction of outcome in patients with metastatic breast cancer remains problematical. The present study evaluated the value of an inflammation-based score (Glasgow Prognostic Score, GPS) in patients with metastatic breast cancer. The GPS was constructed as follows: patients with both an elevated C-reactive protein (>10 mg l<sup>−1</sup>) and hypoalbuminaemia (<35 g l<sup>−1</sup>) were allocated a score of 2. Patients in whom only one or none of these biochemical abnormalities was present were allocated a score of 1 or 0, respectively. In total, 96 patients were studied. During follow-up 51 patients died of their cancer. On multivariate analysis of the GPS and treatment received, only the GPS (HR 2.26, 95% CI 1.45–3.52, P<0.001) remained significantly associated with cancer-specific survival. The presence of a systemic inflammatory response (the GPS) appears to be a useful indicator of poor outcome independent of treatment in patients with metastatic breast cancer.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McMillan, Professor Donald and Doughty, Miss Julie
Authors: Al Murri, A.M., Bartlett, J.M.S., Canney, P.A., Doughty, J.C., Wilson, C., and McMillan, D.C.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing > Clinical Specialities
Journal Name:British Journal of Cancer
ISSN:0007-0920
Published Online:24 January 2006

University Staff: Request a correction | Enlighten Editors: Update this record